Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva)
M Hidalgo, D Bloedow - Seminars in oncology, 2003 - Elsevier
Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva)
M Hidalgo, D Bloedow - Seminars in Oncology, 2003 - infona.pl
Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva).
M Hidalgo, D Bloedow - Seminars in Oncology, 2003 - europepmc.org
Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
[引用][C] Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of erlotinib (Tarceva)
M HIDALGO, D BLOEDOW - Seminars in oncology, 2003 - pascal-francis.inist.fr
Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of erlotinib (Tarceva)
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva)
M Hidalgo, D Bloedow - Seminars in oncology, 2003 - pubmed.ncbi.nlm.nih.gov
Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of erlotinib (Tarceva)
M Hidalgo, D Bloedow - Seminars in oncology, 2003 - pure.johnshopkins.edu
Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
[引用][C] Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva)
M HIDALGO, D BLOEDOW - Seminars in Oncology, 2003 - cir.nii.ac.jp
Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva)
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva)
M Hidalgo, D Bloedow - Seminars in Oncology, 2003 - infona.pl
Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …